Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Deadline Approaching: Apply for the Fierce AI Innovation Awards Pharma Genzyme, Sanofi negotiations remain in low gear By Tracy Staton Aug 16, 2010 10:14am Pharma Biotechnology company Genzyme (NASDAQ: GENZ) may be holding out for more money from suitor Sanofi-Aventis (NYSE: SNY), but it could find it difficult to persuade investors it is better off on its own. Report Pharma
